Clinical Trials Browser

Phase 2 × Prostate Adenocarcinoma × relugolix × Clear all

NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Phase 2 Recruiting

Prostate Adenocarcinoma